Myriad Genetics settles shareholder derivative suit; pays up to $950k in fees, adopts governance reforms

MYRIAD GENETICS INC

Settlement resolves claims that officers misled investors about GeneSight efficacy and study compliance.
Myriad will adopt new disclosure committee charter, CCO job profiles, and amendments to several board committee charters.
Plaintiffs' counsel may seek up to $950,000 in attorneys' fees and costs, paid by Myriad or its insurers.
Court hearing on proposed settlement scheduled for August 6, 2024; defendants deny wrongdoing.
Governance reforms to remain in effect for at least four years from adoption.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.